stoxline Quote Chart Rank Option Currency Glossary
CohBar, Inc. (CWBR)
0.761  0 (0%)    12-01 15:39
Open: 0.6706
High: 1.1
Volume: 33,903
Pre. Close: 0.6706
Low: 0.6706
Market Cap: 2(M)
Technical analysis
2023-12-01 4:19:13 PM
Short term     
Mid term     
Targets 6-month :  1.96 1-year :  2.75
Resists First :  1.68 Second :  2.36
Pivot price 0.83
Supports First :  0.57 Second :  0.48
MAs MA(5) :  0.78 MA(20) :  0.82
MA(100) :  2.4 MA(250) :  2.23
MACD MACD :  -0.3 Signal :  -0.4
%K %D K(14,3) :  37.8 D(3) :  38.2
RSI RSI(14): 32.5
52-week High :  6.9 Low :  0.57
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CWBR ] has closed above bottom band by 45.8%. Bollinger Bands are 61.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.74 - 0.74 0.74 - 0.75
Low: 0.64 - 0.64 0.64 - 0.65
Close: 0.66 - 0.67 0.67 - 0.68
Company Description

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Headline News

Thu, 30 Nov 2023
CohBar, Inc.(OTCPK : CWBR) dropped from S&P TMI Index -

Tue, 28 Nov 2023
Why SenesTech Shares Are Trading Lower By Around 50%? Here ... - UK

Tue, 28 Nov 2023
Why SpringWorks Shares Are Trading Higher By Around 14%; Here ... - MSN

Tue, 28 Nov 2023
North American Morning Briefing : November Rally Pauses Ahead of ... -

Mon, 27 Nov 2023
2023-11-27 | PINL:CWBR | Press Release | CohBar Inc - Stockhouse Publishing

Thu, 02 Nov 2023
U.S. shares higher at close of trade; Dow Jones Industrial Average ... - Australia

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 3 (M)
Shares Float 2 (M)
Held by Insiders 15 (%)
Held by Institutions 2.5 (%)
Shares Short 19 (K)
Shares Short P.Month 29 (K)
Stock Financials
EPS -4.37
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.26
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -48.4 %
Return on Equity (ttm) -84 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.48
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.19
PEG Ratio 0
Price to Book value 0.25
Price to Sales 0
Price to Cash Flow -0.31
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android